Thalidomide NEW
| Price | $50 | $97 |
| Package | 200mg | 500mg |
| Supply Ability: | 10g |
| Update Time: | 2025-05-01 |
Product Details
| Product Name: Thalidomide | CAS No.: 50-35-1 |
| Purity: 99.88% | Supply Ability: 10g |
| Release date: 2025/05/01 |
Product Introduction
Bioactivity
| Name | Thalidomide |
| Description | Thalidomide (Thalomid) is a synthetic derivative of glutamic acid (alpha-phthalimido-glutarimide) with teratogenic, immunomodulatory, anti-inflammatory and anti-angiogenic properties. |
| In vitro | Thalidomide selectively inhibits the production of tumor necrosis factor-alpha (TNF-α) in human monocytes stimulated by lipopolysaccharides and other agonists. Its suppression of TNF-α is mediated through the enhancement of mRNA degradation. Moreover, thalidomide exerts a direct effect on MM cell lines by inducing apoptosis and G1 phase growth arrest, as well as on patient MM cells resistant to melphalan, doxorubicin hydrochloride, and dexamethasone. |
| In vivo | Administering 200mg/kg of Thalidomide resulted in the inhibition of vascularization in the corneal region within rabbits, with the inhibition rate ranging from 30% to 51% across three experiments. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 6.5 mg/mL (25.17 mM), Sonication is recommended. |
| Keywords | TNF-α | Thalidomide | MolecularGlues | Molecular Glues | Ligands for E3 Ligase | LigandforE3Ligase | Ligand for E3 Ligase | Inhibitor | inhibit | E3 ligase-recruiting Moiety | Autophagy | Apoptosis |
| Inhibitors Related | Stavudine | Sodium 4-phenylbutyrate | L-Ascorbic acid | Hydroxychloroquine | Guanidine hydrochloride | L-Glutamic acid | Tributyrin | Valproic Acid | Paeonol | Naringin | L-Ascorbic acid sodium salt | Gefitinib |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
TargetMol Chemicals Inc. is headquartered in Boston, MA, and specializes in products and services that serve the research needs of chemical and biological scientists worldwide. With a client base in 40+ countries, TargetMol has evolved into one of the biggest global research suppliers for compound libraries and small molecule compounds.
170+ Compound Libraries， 10000+ Noval Small Molecucles，16000+ Nature Compounds
TargetMol diligently updates and offers over 170 types of compound libraries and a wide range of high-quality research chemicals, including inhibitors, activators, natural products, peptides, antibodies , and novel life-science kits for laboratory and scientific use. In addition, our lab allows us to conduct CADD (computer-aided drug design) and chemical synthesis to meet the customization needs of our clients.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $97.00 |
VIP6Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $97.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2025-04-29 | ||
|
VIP2Y
|
Shaanxi Dideu New Materials Co. Ltd
|
2025-03-08 | ||
| $120.00 |
Shandong Xuhuang New material CoLTD
|
2025-02-25 | ||
| $35.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2024-04-19 | |
| $10.00 |
Henan Bao Enluo International TradeCo.，LTD
|
2023-06-26 | ||
| $690.00 |
VIP4Y
|
Hebei Dangtong Import and export Co LTD
|
2023-02-17 | |
| $35.00 |
Hebei baicao biology science and technology co., ltd
|
2022-04-06 | ||
| $1.00 |
Guangzhou Biocar Biotechnology Co.,Ltd.
|
2022-01-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, Massachusetts, USA
INQUIRY